FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2240529528> ?p ?o ?g. }

• W2240529528 endingPage "4033" @default.
• W2240529528 startingPage "4033" @default.
• W2240529528 abstract "4033 Background: Pancreatic cancers are resistant to RT. Vascular endothelial growth factor (VEGF) is overexpressed in many tumor types incuding PA. In vivo studies have shown that neutralizing VEGF activity can overcome radioresistance. Methods: Eligible patients for this phase I dose escalation trial had locally advanced, inoperable PA (AJCC 2002 T4, n=45), were inoperable based on pre-referral surgical exploration (T3, n=2) or medical comorbidity (n=1). Prior chemotherapy was allowed (n=25). An initial dose of BV (5 mg/kg IV) was administered 2 weeks prior to RT and every 2 weeks thereafter in successive cohorts of patients (12 patients each at 2.5, 5, 7.5, and 10 mg/kg) during RT (50.4 Gy to the primary tumor with capecitabine [650 mg/m2 PO BID (n = 6); 825 mg/m2 for the remaining patients]. Weekend doses of CAP were omitted in the final 12 patients. BV was continued (5 mg/kg IV q 2 wks) after RT until progression. Results: The worst acute gastrointestinal toxicity was grade 2 in 43% and grade 3 in 5% of patients. Two patients (5%) developed grade 3 hematologic toxicity and 24% developed grade 2 hand and foot syndrome. All patients completed RT and concurrent BV; (43%) of patients had at least a protocol-specified 25% dose reduction of CAP due to toxicity. Three patients had tumor-associated duodenal ulceration with bleeding [3, 10 (fatal), and 20 weeks after RT], and one had a contained duodenal perforation 10 weeks after RT). Primary tumor response: 9 of 41 evaluable had confirmed partial response (22% PR), 7 (17%) had minor response, 24 (59%) had stable disease and 2 (5%) had progressive disease. PR lasted until distant progression (median 6.2 months). Overall, only 5 patients have had local progression. Three patients have safely undergone pancreaticoduodenectomy. Median, 1 yr and 18 mo actuarial survival estimates were 15.7, 65% and 42% from the start of any therapy and 11.6, 45% and 29% from protocol entry. Conclusions: The addition of BV did not significantly increase the acute toxicity of a relatively well-tolerated chemoradiation regimen. Preliminary efficacy results are encouraging. Multiinstitutional studies are planned (RTOG PA 0411 and ACOSOG Z5041). Supported by Genentech Inc. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Labs Genentech" @default.
• W2240529528 created "2016-06-24" @default.
• W2240529528 creator A5016694714 @default.
• W2240529528 creator A5035371911 @default.
• W2240529528 creator A5042286162 @default.
• W2240529528 creator A5042341684 @default.
• W2240529528 creator A5044755649 @default.
• W2240529528 creator A5063061535 @default.
• W2240529528 creator A5082224406 @default.
• W2240529528 creator A5083330124 @default.
• W2240529528 creator A5084420501 @default.
• W2240529528 creator A5087376683 @default.
• W2240529528 date "2005-06-01" @default.
• W2240529528 modified "2023-09-27" @default.
• W2240529528 title "Phase I trial of bevacizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenocarcinoma (PA)" @default.
• W2240529528 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4033" @default.
• W2240529528 hasPublicationYear "2005" @default.
• W2240529528 type Work @default.
• W2240529528 sameAs 2240529528 @default.
• W2240529528 citedByCount "13" @default.
• W2240529528 crossrefType "journal-article" @default.
• W2240529528 hasAuthorship W2240529528A5016694714 @default.
• W2240529528 hasAuthorship W2240529528A5035371911 @default.
• W2240529528 hasAuthorship W2240529528A5042286162 @default.
• W2240529528 hasAuthorship W2240529528A5042341684 @default.
• W2240529528 hasAuthorship W2240529528A5044755649 @default.
• W2240529528 hasAuthorship W2240529528A5063061535 @default.
• W2240529528 hasAuthorship W2240529528A5082224406 @default.
• W2240529528 hasAuthorship W2240529528A5083330124 @default.
• W2240529528 hasAuthorship W2240529528A5084420501 @default.
• W2240529528 hasAuthorship W2240529528A5087376683 @default.
• W2240529528 hasConcept C121608353 @default.
• W2240529528 hasConcept C126322002 @default.
• W2240529528 hasConcept C126894567 @default.
• W2240529528 hasConcept C141071460 @default.
• W2240529528 hasConcept C143998085 @default.
• W2240529528 hasConcept C2776694085 @default.
• W2240529528 hasConcept C2777802072 @default.
• W2240529528 hasConcept C2777909004 @default.
• W2240529528 hasConcept C2780210213 @default.
• W2240529528 hasConcept C29730261 @default.
• W2240529528 hasConcept C509974204 @default.
• W2240529528 hasConcept C526805850 @default.
• W2240529528 hasConcept C71924100 @default.
• W2240529528 hasConcept C90924648 @default.
• W2240529528 hasConceptScore W2240529528C121608353 @default.
• W2240529528 hasConceptScore W2240529528C126322002 @default.
• W2240529528 hasConceptScore W2240529528C126894567 @default.
• W2240529528 hasConceptScore W2240529528C141071460 @default.
• W2240529528 hasConceptScore W2240529528C143998085 @default.
• W2240529528 hasConceptScore W2240529528C2776694085 @default.
• W2240529528 hasConceptScore W2240529528C2777802072 @default.
• W2240529528 hasConceptScore W2240529528C2777909004 @default.
• W2240529528 hasConceptScore W2240529528C2780210213 @default.
• W2240529528 hasConceptScore W2240529528C29730261 @default.
• W2240529528 hasConceptScore W2240529528C509974204 @default.
• W2240529528 hasConceptScore W2240529528C526805850 @default.
• W2240529528 hasConceptScore W2240529528C71924100 @default.
• W2240529528 hasConceptScore W2240529528C90924648 @default.
• W2240529528 hasIssue "16_suppl" @default.
• W2240529528 hasLocation W22405295281 @default.
• W2240529528 hasOpenAccess W2240529528 @default.
• W2240529528 hasPrimaryLocation W22405295281 @default.
• W2240529528 hasRelatedWork W1497385339 @default.
• W2240529528 hasRelatedWork W1965885537 @default.
• W2240529528 hasRelatedWork W1996033399 @default.
• W2240529528 hasRelatedWork W2092651826 @default.
• W2240529528 hasRelatedWork W2145753255 @default.
• W2240529528 hasRelatedWork W2417717847 @default.
• W2240529528 hasRelatedWork W3183798157 @default.
• W2240529528 hasRelatedWork W4240544598 @default.
• W2240529528 hasRelatedWork W4251132435 @default.
• W2240529528 hasRelatedWork W3150826399 @default.
• W2240529528 hasVolume "23" @default.
• W2240529528 isParatext "false" @default.
• W2240529528 isRetracted "false" @default.
• W2240529528 magId "2240529528" @default.
• W2240529528 workType "article" @default.